



Corporate Therapeutic Symposia

These company-based information sessions will provide attendees with non-CME educational opportunities to learn the latest in therapeutics.

Sunday, June 19, 2016

Cynapsus

13:15-14:15

Location: Hall 7.2a Helsinki 1, Level 2

From OFF to ON – Treating Levodopa-Induced OFF Periods

Chairs: C. Warren Olanow
New York, NY, USA

Fabrizio Stocchi
Rome, Italy

Speakers: Anthony Schapira
London, United Kingdom

Karl Kiebertz
New York, NY, USA

C. Warren Olanow
New York, NY, USA

GE Healthcare

13:15-14:15

Location: Hall 7.2a Helsinki 1, Level 2

A Debate on Appropriate Clinical Scenarios for DaT SPECT Imaging

Chair: Stuart Isaacson
Boca Raton, FL, USA

Speakers: Britt Mollenhauer
Kasse, Germany

Angelo Antonini
Padua, Italy

Hubert Fernandez
Cleveland, OH, USA

Monday, June 20, 2016

Adamas

14:00-15:00

Location: Hall 7.2b Budapest, Level 2

Levodopa Induced Dyskinesias: Assessment, Management, and Potential Treatments

Chair: Rajesh Pahwa
Kansas City, MO, USA

Introduction and Program Goals; LID Overview: Risk Factors, Epidemiology, Terminology, and Current Management Strategies

Rajesh Pahwa
Kansas City, MO, USA

LID Burden: How Does It Impact the Patient and Caregiver?

Caroline Tanner
Sunnyvale, CA, USA

Dyskinesia Assessment in Clinical Trials: The UDysRS and Patient Home Diaries

Robert Hauser
Tampa, FL, USA

Zambon

14:00-15:00

Location: Hall A1, Level 1

Safinamide – A Dual Effect to Improve the Management of Motor and Non-Motor Symptoms in Parkinson's Disease

Chairs: Wolfgang Jost
Stuttgart, Germany

C. Warren Olanow
New York, NY, USA

Dual Dopaminergic/Glutamatergic Modulation in Parkinson's Disease

Michele Morari
Ferrara, Italy

Safinamide – A Unique Treatment Targeting Both Dopaminergic and Non-Dopaminergic Systems

Paulo Barone
Naples, Italy

Panel Discussion



International Parkinson and
Movement Disorder Society

20th International Congress of Parkinson's Disease and Movement Disorders

JUNE 19-23, 2016 • BERLIN, GERMANY



Corporate Therapeutic Symposia

Monday, June 20, 2016, cont.

Britannia

14:00-15:00

Location: Hall A8, Level 1

How Can We Enhance Patient Outcomes With Current Therapies? Practical Approaches to Treatment Optimization in Parkinson's Disease

Chair: Claudia Trenkwalder
Kassel, Germany

Optimizing ON Time in Early Parkinson's Disease

Stuart Issacson
Boca Raton, FL, USA

The Importance of Patient Selection and Monitoring with
Continuous Dopaminergic Therapy

Georg Ebersbach
Beelitz-Heilstatten, Germany

Tuesday, June 21, 2016, cont.

AbbVie

14:00-15:00

Location: Hall A1, Level 1

Empowering Patients for Clinical Decision- Making in Advanced Parkinson's Disease

Chair: Werner Poewe
Innsbruck, Austria

Considering Timing of Device-Aided Therapies -
Having Patients' Quality of Life in Mind

Angelo Antonini
Venice, Italy

The Spectrum of Patients for Device-Aided Therapies -
Clinical Data and Practical Considerations

K. Ray Chaudhuri
London, United Kingdom

When and How to Educate Patients on Device-Aided
Therapies - The Art of Making Informed Decisions

Alexander Storch
Rostock, Germany

Tuesday, June 21, 2016

Ipsen

14:00-15:00

Location: Hall 7.2b Budapest, Level 2

Cervical Dystonia Management with BoNT-A: Towards an Optimized Approach

Chair: David M. Simpson
New York, NY, USA

American Academy of Neurology Evidence Based
Guidelines 2016 Update

David M. Simpson
New York, NY, USA

New Approaches to Differentiate and Treat Cervical
Dystonia

Wolfgang Jost
Freiburg, Germany

Simplifying Injection Parameters for Botulinum Toxin in
Cervical Dystonia: A Personal Experience

Marion Simonetta-Moreau
Toulouse, France

ACADIA Pharmaceuticals

14:00-15:00

Location: Hall A8, Level 1

Treating the Hallucinations and Delusions Associated With Parkinson's Disease Psychosis

Daniel E. Kremens
Philadelphia, PA, USA

Rajesh Pahwa, MD
Kansas City, MO, USA

*Due to the German Medicinal Products Act, attendance to this session is limited
to delegates from the United States.*



Corporate Therapeutic Symposia

Wednesday, June 22, 2016

Bial

13:30-14:30

Location: Hall 7.2b Budapest, Level 2

Are We Fulfilling the Needs of Patients with Motor Fluctuations? The Role of COMT Inhibition

Chair: Joaquim Ferreira
Lisbon, Portugal

Levodopa Motor Fluctuations and Current Treatment Strategies

Eduardo Tolosa
Barcelona, Spain

COMT Inhibition: Strengths and Weaknesses

Fabrizio Stocchi
Rome, Italy

Developments in COMT Inhibitors

Olivier Rascol
Toulouse, France

Medtronic

13:30-14:30

Location: Hall A1, Level 1

Who Wants to be a DBS Master – Three DBS Experts Sharing Their Knowledge From Diagnosis to Follow Up Through a Quiz Show That Asks the Audience for Help

Chair/
Players: Bastiaan Bloem
Nijmegen, Netherlands

Lars Timmermann
Cologne, Germany

Stephan Chabardes
Grenoble, France

Wednesday, June 22, 2016, cont.

Acorda Therapeutics

13:30-14:30

Location: Hall A8, Level 1

The Many Faces of OFF

Chair: Matthew Stern
Philadelphia, PA, USA

The Many Faces of OFF

Anthony Lang
Toronto, ON, Canada

Primary Causes of Motor Fluctuations in PD

Peter LeWitt
Detroit, MI, USA

Emerging Levodopa Strategies to Address Motor Fluctuations

Robert Hauser
Tampa, FL, USA

Thursday, June 23, 2016

Teva Pharmaceuticals

13:30-14:30

Location: Hall A1, Level 1

Emerging Therapies and Technologies in Movement Disorders

Chair: Bernhard Landwehrmeyer
Ulm, Germany

Digital Health Technology

Ralf Reilmann
Münster, Germany

Dueteration Technology: SD-809 in Tourette's Syndrome

Joseph Jankovic
Houston, Texas

Dueteration Technology: SD-809 in Tardive Dyskinesia

Hubert Fernandez
Cleveland, OH, USA